Diastolic Heart Failure Clinical Trial
Official title:
Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure
This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.
To evaluate the effect of breathing training on the 6-minute walk test in a population of heart failure patients. Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur. - Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breathing therapy) or the control (standard of care). - N-terminal (NT)-pro hormone BNP (NT-proBNP): If an NT-proBNP was collected as standard of care within 3 months of enrollment, this can be used for study purposes and compared to the 6 month NT-proBNP. - New York Heart Association Class: If the NYHA class is completed as standard of care within 3 months of enrollment, this can be used for study proposes. - Kansas City Cardiomyopathy Questionnaire (KCCQ) - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Orientation to the Heart Rate Variability 4 (HRV4) Training application: This will include downloading, creating an account for, and training the participant on the application. The Intervention Group will also receiving training on the Meo Health breathing therapy, which will include: - Being shown the Meo Health Breathing Therapy On-Boarding video - Orientation to breathing application: Participants will be assisted in downloading and custom setting the Breathe application. - Zoom Within one month of the baseline visit, participants in the intervention group will have a one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their breathing therapy intervention. 3 Month Visit The 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group . The participant will only meet with the CRC at the 3 month visit and all assessments will be completed by the CRC. - NYHA class - KCCQ - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Assess compliance from HRV4 Training application questions - Assess any possible adverse events 6 Month/Final Visit The 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group. The participant will meet with the CRC at the 6 month visit, any assessments not completed as Standard of Care (SOC), will be completed by the CRC. - NT-proBNP: If an NT-proBNP is ordered as standard of care for the participant, this can be used for study purposes and compared to the baseline NT-proBNP. - NYHA class: If the NYHA class is completed as standard of care, this can be used for study purposes and compared to the baseline and 3 month values. - KCCQ - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Assess any possible adverse events 9 Month Structured Telephone Survey The 9 month structured telephone interview will take place for all participants who receive breathing training from Meo Health. Participants will be called by a study team member who will facilitate a short (3-5 minute) telephone survey about adherence and changes in health outcomes as a result of participation in the trial. (See appendix 15.4). The study team member will record all answers into REDCap. Upon completion of the survey, participants will be closed out of the study. If a study team member is unable to get in contact with a participant after two attempts, their status will be marked as "closed to follow-up" and they won't be interviewed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02499601 -
CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)
|
N/A | |
Completed |
NCT02537041 -
Non-invasive Evaluation of Myocardial Stiffness by Elastography
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Withdrawn |
NCT00773084 -
Aliskiren and Renin Inhibition in Diastolic Heart Failure
|
N/A | |
Terminated |
NCT00293150 -
Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure
|
Phase 4 | |
Terminated |
NCT01942395 -
Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)
|
N/A | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Terminated |
NCT01778894 -
Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart
|
||
Completed |
NCT04154878 -
2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
|
||
Recruiting |
NCT01599117 -
A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]
|
Phase 3 | |
Completed |
NCT01185067 -
Physiological Effects of Grape Seed Extract in Diastolic Heart Failure
|
Phase 1 | |
Completed |
NCT03338374 -
Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Completed |
NCT02589977 -
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
|
Phase 4 | |
Completed |
NCT02147613 -
High Intensity Interval Exercise in Diastolic Heart Failure
|
N/A | |
Terminated |
NCT00083772 -
Use of Nesiritide in the Management of Acute Diastolic Heart Failure
|
Phase 4 | |
Completed |
NCT00303498 -
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
|
Phase 2 | |
Terminated |
NCT02254382 -
Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure
|
N/A | |
Completed |
NCT00839228 -
Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome
|
Phase 2 | |
Terminated |
NCT00662116 -
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
|
Phase 2 | |
Completed |
NCT02084992 -
A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure
|
N/A |